Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Shi Yin WongAinsley Ryan Yan Bin LeeAaron Hon Jiun SiaYu Jun WoYao Hao TeoYao Neng TeoNicholas L SynChing-Ching OngLynette L TeoTiong-Cheng YeoKian-Keong PohWilliam K KongRaymond C WongChing-Hui SiaPublished in: Cardiovascular drugs and therapy (2022)
GLP-1RA drugs may improve systolic and diastolic function in type 2 diabetes and reduce infarct size post-acute myocardial infarction with no demonstrable effect on cardiac function in heart failure. Tailored recommendations for the use of GLP-1RAs for cardioprotection should be considered for each patient's condition.
Keyphrases
- left ventricular
- acute myocardial infarction
- heart failure
- type diabetes
- cardiac resynchronization therapy
- rheumatoid arthritis
- blood pressure
- disease activity
- case report
- cardiovascular disease
- ankylosing spondylitis
- glycemic control
- clinical practice
- smoking cessation
- systemic lupus erythematosus
- acute coronary syndrome
- metabolic syndrome
- atrial fibrillation
- coronary artery disease
- adipose tissue